Publicaciones en colaboración con investigadoras/es de Karolinska University Hospital (47)

2024

  1. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes

    Journal of Crohn's and Colitis, Vol. 18, Núm. 3, pp. 349-359

  2. Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 5, pp. 994-1004.e10

2023

  1. A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 709-726

  2. Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations

    Nature Communications, Vol. 14, Núm. 1

  3. Corrigendum to “Dissecting the genetic heterogeneity of gastric cancer” (eBioMedicine (2023) 92, (S2352396423001810), (10.1016/j.ebiom.2023.104616))

    eBioMedicine

  4. Dissecting the genetic heterogeneity of gastric cancer

    eBioMedicine, Vol. 92

  5. Evaluating the Construct of Damage in Systemic Lupus Erythematosus

    Arthritis Care and Research, Vol. 75, Núm. 5, pp. 998-1006

  6. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases

    The Lancet Rheumatology

  7. Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study

    Hepatology, Vol. 77, Núm. 2, pp. 512-529

2022

  1. Current clinical practice for thromboprophylaxis management in patients with Cushing’s syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN)

    Orphanet Journal of Rare Diseases, Vol. 17, Núm. 1

2021

  1. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders

    Nature Genetics, Vol. 53, Núm. 11, pp. 1543-1552

  2. Impact of glucocorticoids on the incidence of lupus-related major organ damage: A systematic literature review and meta-regression analysis of longitudinal observational studies

    Lupus Science and Medicine, Vol. 8, Núm. 1

2020

  1. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

    Arthritis and Rheumatology, Vol. 72, Núm. 1, pp. 67-77

  2. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus

    Journal of Autoimmunity, Vol. 106

2019

  1. A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires

    Clinical Pharmacology and Therapeutics, Vol. 106, Núm. 2, pp. 374-382

  2. EULAR recommendations for the management of antiphospholipid syndrome in adults

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 10, pp. 1296-1304

  3. Osteopontin and disease activity in patients with recent-onset systemic Lupus Erythematosus: Results from the SLICC Inception Cohort

    Journal of Rheumatology, Vol. 46, Núm. 5, pp. 492-500

  4. Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II)

    Revista Espanola de Cardiologia, Vol. 72, Núm. 12, pp. 1020-1030

  5. The tumour microenvironment and immune milieu of cholangiocarcinoma

    Liver International, Vol. 39, Núm. S1, pp. 63-78

  6. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

    Antiviral Research, Vol. 170